Jim Hughes

Life Raft Group. Daughter Nancy (1967-2005) SDH-deficient GIST. Veteran. Telecom career. Community advocate. Literacy matters. @tjh43.bsky.social

[Jim Hughes @TJH43]

Characterization of hereditary tumor risk in individuals with SDHA germline variants. | Journal of Clinical Oncology https://t.co/rjYaz1lTb7

[Jim Hughes @TJH43]

Single Nuclei-Derived Molecular Subtypes of Gastrointestinal Stromal Tumors Correlate with Clinicopathologic Features and Predict Clinical Outcomes | bioRxiv https://t.co/5csKVDRsVR

[Jim Hughes @TJH43]

Genome‐Wide DNA Methylation and Copy Number Alterations in Gastrointestinal Stromal Tumors - Kleijn - 2025 - Genes, Chromosomes and Cancer - Wiley Online Library https://t.co/8OMpPlafoD

[Jim Hughes @TJH43]

Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles | Nature Communications https://t.co/cL4YTkjBoi

[Jim Hughes @TJH43]

Recent Advances in Succinate Dehydrogenase Deficient Gastrointestinal Stromal Tumor Systemic Therapies | Current Treatment Options in Oncology https://t.co/Kzrg5NATkK

[Jim Hughes @TJH43]

A Review of Genomic Testing and SDH‐ Deficiency in Gastrointestinal Stromal Tumors: Getting to the GIST - Florou - 2025 - Cancer Medicine - Wiley Online Library https://t.co/StJWoNoHAq

[Jim Hughes @TJH43]

Cracking the code of DNA circles in cancer, Stanford Medicine-led team uncovers potential therapy | News Center | Stanford Medicine https://t.co/H4Fx1hhvjd

[Jim Hughes @TJH43]

Autocrine IGF-II-Associated Cancers: From a Rare Paraneoplastic Event to a Hallmark in Malignancy https://t.co/OLVeCNaVFo

[Jim Hughes @TJH43]

Clinical characteristics of gastrointestinal stromal tumors with hypoglycemia https://t.co/qzJKm1QmUZ

[Jim Hughes @TJH43]

Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST) | Kura Oncology, Inc. https://t.co/31bEA2NoJE(GLOBEhttps://www.atlassian.com/software/confluence/comparison/confluence-vs-notion

[Jim Hughes @TJH43]

Dissection of a CTCF topological boundary uncovers principles of enhancer-oncogene regulation: Molecular Cell https://t.co/JFM7T1fLKs

[Jim Hughes @TJH43]

"ClinVar currently has more than 3000 entries for VUS in SDHx genes." ...
"Our findings open up new diagnostic options for the identification of carriers with SDHx PVs and could aid in classification of VUS in SDHx genes."

[Jim Hughes @TJH43]

Identification of Succinate Dehydrogenase Gene Variant Carriers by Blood Biomarkers https://t.co/Qw6rOxqDSU

[Jim Hughes @TJH43]

Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial - The Lancet Oncology https://t.co/bzxG2qug9c

[Jim Hughes @TJH43]

Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles - nihpp-rs4410500v1.pdf https://t.co/ama7Squ2Cp

[Jim Hughes @TJH43]

Pre-clinical phaeochromocytoma and paraganglioma models: Cell lines, animal models, and a human primary culture model - ScienceDirect https://t.co/NFqBc2udg0

A map of pathogenic variants and currently available cell lines and primary cultures ... Figure 1

[Jim Hughes @TJH43]

Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable? - Sutton - Journal of Surgical Oncology - Wiley Online Library https://t.co/RxwwTqlGeH

[Jim Hughes @TJH43]

A PDE3A-SLFN12 Molecular Glue Exhibits Significant Antitumor Activity in TKI-Resistant Gastrointestinal Stromal Tumors | Clinical Cancer Research | American Association for Cancer Research https://t.co/UwerdgNNAo

[Jim Hughes @TJH43]

Prevalence and prognosis of hypoxia‐inducible factor‐2α (HIF‐2α) pathway gene mutations across advanced solid tumors - CAM4-13-e7358.pdf https://t.co/vWtlAw5Vm2

[Jim Hughes @TJH43]

Targetable Receptor Tyrosine Kinase in Metastatic Pheochromocytoma and Paraganglioma: A Future Journey for Anlotinib? | Journal of the Endocrine Society | Oxford Academic https://t.co/echi2ue5QC